Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society.
The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly,...
| Publicado en: | Archives of Pathology & Laboratory Medicine Vol. 142; no. 3; pp. 408 - 420 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | tables/charts Journal Article |
| Publicado: |
College of American Pathologists
Mar2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=128325463&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 128325463 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00039985 1FS jtl: Archives of Pathology & Laboratory Medicine issn: 00039985 maglogo: N pubinfo: dt: Mar2018 vid: 142 iid: 3 pid: 2550 pub: College of American Pathologists place: Northfield, Illinois artinfo: ui: 128325463 128325463 128325463 10.5858/arpa.2017-0106-SA 128325463 ppf: 408 ppct: 12 formats: fmt: @attributes: type: P tig: atl: Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. aug: au: Thunnissen, Erik Allen, Timothy Craig Adam, Julien Aisner, Dara L. Beasley, Mary Beth Borczuk, Alain C. Cagle, Philip T. Capelozzi, Vera Luiza Cooper, Wendy Hariri, Lida P. Kern, Izidor Lantuejoul, Sylvie Miller, Ross Mino-Kenudson, Mari Radonic, Teodora Raparia, Kirtee Rekhtman, Natasha Roy-Chowdhuri, Sinchita Russell, Prudence Schneider, Frank affil: Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands sug: subj: Immunohistochemistry Biological Markers Lung Diseases Membership Decision Making, Clinical Carcinoma, Non-Small-Cell Lung Antigens, Surface ab: The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK and programmed death ligand-1 (PD-L1) (ROS1, EGFR in Europe) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes. pubtype: Academic Journal doctype: tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|